drugset / Trial / NCT07185399
Systems Biological Analysis of Immune Responses to RSV Vaccine
NaSingle-groupOpen-labelBasic science
Summary
The purpose of this study is to characterize the immune response to the FDA-approved mRNA-based RSV vaccine in adults ≥60 years of age, using a systems biology approach. The study aims to generate high-resolution immunologic and systems biology data following vaccination to identify early biomarkers of response and gain mechanistic insight into host immunity.
Timeline
- Start
- 2025-10-13
- Primary completion
- 2026-07
- Completion
- 2026-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MRESVIA | Messenger RNA (mRNA) | 50 ug | Intramuscular |
| Subject | MRESVIA | Messenger RNA (mRNA) | 0.5 ml | Intramuscular |